SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending as traders discuss its potential as a crypto treasury play following news of a $300M private placement, with community members comparing it to previous runners like $QMMM. Bullish sentiment is fueled by the company's plans to rebrand as Solmate and focus on Solana-based digital assets, while others caution about potential dilution and the sustainability of the rally. The stock's low float and volatile price action are also driving considerable conversation.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

LEN is trending due to a mixed earnings report, with community members debating whether increased orders offset squeezed margins. Discussions also focus on lowered guidance and the potential impact of interest rate cuts on the housing market. The stock's price movement and future commentary from the company are key points of interest for investors.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx ($FDX) is trending following its Q1 earnings release, which featured a better-than-expected EPS and revenue. Despite the earnings beat, the stock dipped in after-hours trading as community members discuss the company's soft guidance and concerns around global trade and tariffs. Some traders are speculating about a potential short squeeze and monitoring the upcoming conference call for further insights.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Disney is trending due to a boycott spurred by the reported suspension of Jimmy Kimmel from ABC, generating heated debate about free speech and political bias. The community is divided, with some supporting the boycott and others arguing it's an overreaction or politically motivated. Broader concerns around Disney's content and business decisions are also being discussed alongside the immediate controversy.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors weigh the potential impact of FedEx's earnings and broader concerns about shipping volumes and costs. Community discussions revolve around the stock's high dividend yield and whether it can be sustained, along with speculation about a potential bottom and future price targets. Some traders are also discussing the impact of US-China trade tensions on shipping demand for UPS.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amid discussions around Panasonic's anode-free solid-state battery announcement, with investors speculating about a potential partnership with QS and Tesla. The community is analyzing patent landscapes and commercialization timelines, debating whether this signals validation or competition for QS's technology. Bullish sentiment suggests a possible breakthrough for solid-state batteries, while bears caution about execution risks and insider selling.

༼ つ ◕_◕ ༽つ gib is a meme coin on Hedera, inspired by the classic copy pasta meme of persistence and community. Born from the viral 2013 Dota 2 Diretide event, gib embodies the power of collective action. As one of the first ASCII-named tokens on-chain, gib merges meme culture with blockchain innovation, helping users explore Hedera, crypto, and tech in a fun, engaging way. ༼ つ ◕_◕ ༽つ gib knowledge

GIB.X is trending as community members tout its potential within the Hedera ($HBAR.X) ecosystem, drawing comparisons to the success of other meme coins like $PENGU.X and $DOGE.X. Discussions highlight GIB's low market cap, recent incorporation, and the possibility of exchange listings as potential catalysts for significant growth, positioning it as a leading memecoin on the Hedera network.

Darden Restaurants, Inc. is a full-service restaurant company, which engages in the provision of restaurant services. It operates through the following segments: Olive Garden, LongHorn Steakhouse, Fine Dining, and Other Business. The Olive Garden segment is the largest full-service dining Italian restaurant operator. The LongHorn Steakhouse segment includes the results of the company-owned LongHorn Steakhouse restaurants. The Fine Dining segment consists of the premium brands that operate within the fine-dining sub-segment of full-service dining and includes the results of its company-owned The Capital Grille and Eddie V's restaurants. The Other Business segment aggregates the remaining brands and includes the results of its company-owned Cheddar's Scratch Kitchen, Yard House, Seasons 52 and Bahama Breeze restaurants, and from franchises and consumer-packaged goods sales. The company was founded by William B. Darden in 1938 and is headquartered in Orlando, FL.

Darden Restaurants, Inc.

Darden Restaurants ($DRI) is trending amid mixed reactions to recent earnings and revenue figures, with some analysts anticipating price target increases. Community discussions highlight momentum traders observing strong tape action and potential range expansion, while others focus on short positions around a key price level. The broader context includes potential catalysts from clean tech initiatives and utility pilot markets.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending due to community discussion around new government contracts for medical countermeasures, particularly for anthrax and smallpox, sparking optimism about revenue growth and potential short squeezes. There's also speculation about international expansion and the company's role in biodefense, alongside frustration over the stock's recent performance despite positive developments. Some investors are analyzing technical indicators like the golden cross, while others express concern about short selling and potential manipulation.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR.X is trending as the community anticipates a breakout, fueled by discussions around AI integration and potential for new all-time highs. Positive sentiment is building, with many highlighting its undervalued status and setting price targets, while some traders pointing out its lack of momentum compared to other altcoins. Recent news around cross-chain capabilities and validator voting on inflation are also being closely watched.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now?

Does Xeris Biopharma (XERS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

Xeris Biopharma (XERS) delivered earnings and revenue surprises of +66.67% and +10.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?

Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

Xeris Biopharma - Possibly the best Pharma Stock

Summary Xeris Biopharmaceuticals has shown strong technical buy signals, with a 30.03% gain since the Trend Seeker buy signal on 1/28. The company offers innovative therapies like Gvoke, Keveyis, and Recorlev, and is developing XP-8121 and XeriSol/XeriJect technologies. Barchart indicators show 100% technical buy signals, a 95.32% gain in the...

Shares of Xeris Biopharma Inc. surged more than 9.5% on Thursday, reaching their highest level since June 2021, driven by a better-than-expected revenue forecast for 2025 that fueled investor optimism.&nbsp;The rally came despite a slightly wider-than-expected quarterly loss, with retail sentiment increasingly bullish following the earnings release.Xeris reported an adjusted fourth-quarter loss of $0.03 per share, narrowly missing Wall Street expectations of a $0.02 loss.&nbsp;However, revenue for the period was $60.01 million, exceeding the consensus estimate of $58.54 million.&nbsp;The company's full-year guidance emerged as the key driver of market enthusiasm. Xeris expects 2025 revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.CEO John Shannon described 2024 as an "exceptional" year, as revenue surpassed $203 million to a record high.&nbsp;CFO Steven Pieper said record quarterly revenue of more than $60 million in&nbsp;Q4 contributed to a positive cash flow of $2 million and adjusted&nbsp;earnings before interest, taxes, depreciation, and amortization (EBITDA) of over $8 million.&nbsp;He added that the 2025 revenue outlook represents more than 30% growth at the midpoint.Xeris currently markets three key products: Recorlev for endogenous Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis.&nbsp;It is also advancing a pipeline of development programs, led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, alongside several early-stage programs leveraging its technology platforms.On Stocktwits, sentiment for Xeris turned 'extremely bullish' (89/100) and reached its highest score in a year, with message volume surging by 780% in the 24 hours to Thursday's close.&nbsp;<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/XERS_sentiment_and_message_volume_as_of_March_6_14ecb19082.png" alt="XERS sentiment and message volume as of March 6.png" width="1316" height="302"><figcaption>XERS sentiment and message volume as of March 6 | source: Stocktwits</figcaption></figure>One user noted that the stock's long period of stagnation, "like 40 qtrs in the desert," had finally given way to momentum.&nbsp;<stembedurl>https://stocktwits.com/NobVega/message/607012972</stembedurl>Another speculated about the possibility of a buyout, suggesting that Xeris could attract an acquisition offer by the end of the year.<stembedurl>https://stocktwits.com/Finwizard61/message/607030000</stembedurl>Short interest in Xeris last stood at 6.9%, according to Koyfin data. The company's stock, which was falling after-hours on Thursday, has gained nearly 22% since the start of the year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.

Equity

The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected.


Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

XERS
Xeris Biopharma Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest XERS News

XERS Xeris Biopharma Holdings Inc